Skip to main content
. 2022 Jul 4;12:11298. doi: 10.1038/s41598-022-15378-1

Figure 3.

Figure 3

Comparison between the in-house ELISA qualitative results and those of the automated tests Vidas SARS-CoV-2 IgG anti-RBD Biomérieux and Elecsys Anti-Nucleocapsid of SARS-CoV-2 Roche.